Science & Technology Platform
ImmunoBiochem utilizes modern computational tools and robust disease models to develop novel degrader-antibody conjugate (DAC) therapeutics for precision immunology. DACs access unique mechanisms via targets on both the surface and inside disease-driving cells, not accessible to other modalities, with a multi-modal layered logic-gated control of selectivity and potency for precise regulation of immunobiology. ImmunoBiochem’s synthetic payloads, designed with controlled targeted protein degradation catalytic activity, enable unparalleled in vivo programming of biology. Accelerated by modern computational tools and AI, tunable heterofunctional chemistry enables precise engineering of novel non-cytotoxic DAC payloads with favourable biophysical, pharmacological and biological properties, overcoming all of the limitations of ADC payloads like CMC challenges and narrow therapeutic index and unlocking more favorable routes of administration, like subcutaneous delivery.
ImmunoBiochem’s novel DACs are designed to drive unprecedented efficacy, while avoiding the significant side-effects of other modalities. IMB216P, lead molecule for autoimmune disorders, is a CD127/IL7RA-targeted DAC with a JAK1/TYK2 dual-degrader payload that carries out immune system reset and rebalancing at the level of disease-driving T cells, and without lymphodepletion or broad immunosuppression. IMB216P has potential across all major autoimmune indications, including, in IBD, PsO, PsA, SLE, LN, T1D, RA, JIA, SpA, IPF, SjD, GvHD and MS.
